SCHEMBL14855083

SCHEMBL14855083

Nc1ccc(OCc2ccccc2Cl)c(Cl)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.50
MAPT P10636 2/20 0.49
MPO P05164 1/20 0.49
MRGPRX4 Q96LA9 2/20 0.48
MAOB P27338 1/20 0.48
SLC6A4 P31645 2/20 0.47
SYK P43405 1/20 0.47
HPGD P15428 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
NPC1 O15118 1/20 0.46
NFKB1 P19838 1/20 0.46
RAB9A P51151 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
HDAC8 Q9BY41 2/20 0.46
TP53 P04637 1/20 0.45
HTT P42858 1/20 0.45
HTR6 P50406 1/20 0.45
FFAR1 O14842 1/20 0.45
FFAR4 Q5NUL3 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27911213 0.87 CA1 (0.50) IDO1MAPTMRGPRX4SYKHPGD
SCHEMBL14854759 0.86 MAOB (0.48) IDO1MAPTMPOMAOBSLC6A4
SCHEMBL8807329 0.86 IDO1 (0.46) IDO1MAPTMRGPRX4SLC6A4SYK
SCHEMBL3319862 0.86 MAPT (0.60) IDO1MAPTMPOMRGPRX4MAOB
SCHEMBL12173112 0.86 MRGPRX4 (0.45) MAPTMRGPRX4SYKSMN1; SMN2NPC1
SCHEMBL7886546 0.84 IDO1 (0.50) IDO1MAPTMRGPRX4SYKHPGD
SCHEMBL2748596 0.82 MRGPRX4 (0.52) IDO1MAPTMRGPRX4MAOBSLC6A4
SCHEMBL2748578 0.82 PLAU (0.50) MAPTMRGPRX4MAOBSYKSMN1; SMN2
SCHEMBL20535794 0.81 IDO1 (0.52) IDO1MAPTMPOMAOBSLC6A4
SCHEMBL632895 0.81 MRGPRX4 (0.57) MAPTMRGPRX4MAOBSYKSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3222620-B1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) 2019-11-20 EP disclosed
EP-3222620-B1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) 2019-11-20 EP disclosed
US-10246443-B2 Cyanoquinoline derivatives TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2019-04-02 US disclosed
US-10246443-B2 Cyanoquinoline derivatives TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2019-04-02 US disclosed
EP-3222620-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2017-09-27 EP disclosed
EP-3222620-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2017-09-27 EP disclosed
US-20170226093-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2017-08-10 US disclosed
US-20170226093-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2017-08-10 US disclosed
US-20170226093-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2017-08-10 US disclosed
US-9676724-B2 Cyanoquinoline derivatives TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2017-06-13 US disclosed
US-20160185728-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2016-06-30 US disclosed
US-20160185728-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO., LTD. (CN) 2016-06-30 US disclosed
US-9187458-B2 Cyanoquinoline derivatives TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2015-11-17 US disclosed
US-9187458-B2 Cyanoquinoline derivatives TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2015-11-17 US disclosed
US-20130225579-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2013-08-29 US disclosed
US-20130225579-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2013-08-29 US disclosed
US-20130225579-A1 CYANOQUINOLINE DERIVATIVES TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2013-08-29 US disclosed
EP-2581372-A1 CYANOQUINOLINE DERIVATIVES Tianjin Hemay Bio-Tech Co., Ltd. (CN) 2013-04-17 EP disclosed
EP-2581372-A1 CYANOQUINOLINE DERIVATIVES Tianjin Hemay Bio-Tech Co., Ltd. (CN) 2013-04-17 EP disclosed
WO-2011153942-A1 CYANOQUINOLINE DERIVATIVES 天津和美生物技术有限公司 (CN) 2011-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10246443-B2 Cyanoquinoline derivatives CBR3, CYP3A4, CDK1 IDO1 1594/4885MAPT 43/4885MPO 4290/4885
US-20130225579-A1 CYANOQUINOLINE DERIVATIVES CBR3, CYP3A4, CDK1 IDO1 1594/4885MAPT 43/4885MPO 4290/4885
US-20160185728-A1 CYANOQUINOLINE DERIVATIVES CBR3, CYP3A4, CDK1 IDO1 1594/4885MAPT 43/4885MPO 4290/4885
US-20170226093-A1 CYANOQUINOLINE DERIVATIVES CBR3, CYP3A4, CDK1 IDO1 1594/4885MAPT 43/4885MPO 4290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.